A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Open accessPublished version of a preprint
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance. Significance: The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial. This article is highlighted in the In This Issue feature, p. 873
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SIG2 contained Lachnospiraceae (species from the genus Blautia, Roseburia, Dorea, and Eubacterium) and Oscillospiraceae family members (Faecalibacterium prausnitzii, Ruminococcus bicirculans, and R. lactaris), which were previously associated with general health and favorable clinical responses to ICIs.”
From Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome (2024) · cites this paper as Messaoudene et al., 2022
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These trials have been inspired by the observation that castalagin selectively binds to a Ruminococcus species with immunostimulatory properties and propagates its expansion in preclinical models 51”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Castalagin was also found to enrich Ruminococcaceae and A. muciniphila in the gut microbiota.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Messaoudene et al., 2022
In the citing paper
“For example, supplementation with castalagin, a polyphenol and the active compound in the camu-camu berry (Myrciaria dubia), enhanced antitumor immune responses and improved anti-PD-1 efficacy in preclinical models (Messaoudene et al., 2022).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Messaoudene et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“DESeq2 (35) was used to perform differential abundance analysis at the genus level.”
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 10×
“muciniphila, which predicted the response in 153 patients with advanced NSCLC and renal cell cancer amenable to ICI (10).”
BackgroundMethodInfluentialSelf-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 2×
“Recent metagenomic sequencing studies coupled with experiments in germ-free (GF) mice have revealed that the gut microbiome serves as another key mediator of this cancer-immune set point (5, 6).”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“bromii were associated with an increased proportion of CD8+ T cells in the tumor and peripheral blood and correlated with a beneficial response (12).”
BackgroundNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Third, we used fecal samples from mice treated with or without CC to perform daily FMT in SPF mice over the course of 14 days after MCA-205 inoculation (10, 21).”
MethodSelf-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 1×
“muciniphila were both enriched post-FMT in R patients with melanoma refractory to ICI (18, 34).”
BackgroundFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · cited 2×
“muciniphila were both enriched post-FMT in R patients with melanoma refractory to ICI (18, 34).”
BackgroundGut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508 · cited 1×
“Moreover, secondary taurinated bile acids are known to inhibit colon adenoma (27) and are decreased after ATB treatment, which has also been associated with ICI resistance (28).”
BackgroundA Review of the Antioxidant Mechanisms of Polyphenol Compounds Related to Iron Binding
Perron, N. R., & Brumaghim, J. L. (2009) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-009-9043-x · Cited by 1,370 · cited 1×
“Polyphenols can also chelate ferric iron via their catechol moieties, which may provide an advantage in an iron-deprived environment (33).”
BackgroundNatural Polyphenols (Vegetable Tannins) as Drugs: Possible Modes of Action
Haslam, E. (1996) · Journal of Natural Products · doi:10.1021/np960040+ · Cited by 1,302
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200 · cited 1×
“Taken together, these observations have initiated efforts to harness the gut microbiome as a therapeutic adjuvant to ICI (16).”
BackgroundA defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145 · cited 1×
“Furthermore, a consortium of 11 beneficial gut bacteria induced a stronger CD8+ T-cell and IFNγ immune response in the colon of mice and improved ICI activity (14).”
BackgroundPitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041 · cited 1×
“Defining mechanisms of resistance implicates several factors, including PD-L1 expression, tumor microenvironment contexture, and the tumor mutational burden determining the cancer-immune set point or threshold (4, 5).”
BackgroundSelf-citationDerosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
Self-citationDerosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · cited 2×
“Therefore, we sought to demonstrate an interaction between castalagin and Ruminococcus, which is known to be beneficial for patients with cancer amenable to ICI (25).”
BackgroundSelf-citationThe gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523 · cited 1×
“Recent metagenomic sequencing studies coupled with experiments in germ-free (GF) mice have revealed that the gut microbiome serves as another key mediator of this cancer-immune set point (5, 6).”
BackgroundSelf-citationDerosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.044 · Cited by 398 · cited 1×
“muciniphila in mice initially colonized with FMT from nonresponder (NR) patients was shown to enhance the efficacy of ICI (10, 13).”
BackgroundSelf-citationHakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316 · cited 1×
“org to ICI initiation decreased gut microbiome diversity and decreased the presence of Ruminococcaceae in patients with advanced non–small cell lung cancer (NSCLC) and led to unfavorable outcomes (15).”
BackgroundSelf-citationWhere in the world do bacteria experience oxidative stress?
Imlay, J. A. (2019) · Environmental Microbiology · doi:10.1111/1462-2920.14445 · Cited by 313 · cited 1×
“Thus, bacteria that associate with castalagin may be protected from ROS present at the oxic–anoxic interface of the intestinal epithelium (31, 32).”
BackgroundAnhê, F. F., Nachbar, R. T., Varin, T. V., Trottier, J., Dudonné, S., Le Barz, M., Feutry, P., Pilon, G., Barbier, O., Desjardins, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315565 · Cited by 267
Self-citationFracassetti, D., Costa, C., Moulay, L., & Tomás-Barberán, F. A. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.01.121 · Cited by 256 · cited 3×
“Castalagin Is the Bioactive Polyphenol Molecule from CC That Is Responsible for Its Antitumor Effect CC is composed of more than 50 compounds, including multiple polyphenols that can all contribute to its prebiotic properties (22).”
BackgroundMethodInfluentialSelma, M. V., Beltrán, D., Luna, M. C., Romo-Vaquero, M., García-Villalba, R., Mira, A., Espín, J. C., & Tomás-Barberán, F. A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01521 · Cited by 211
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
Self-citationHelicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323392 · Cited by 176 · cited 1×
“Lastly, an in vivo CD8+ T-cell killing assay was performed after mice received an intravenous injection of carboxyfluorescein succinimidyl ester (CSFE)–labeled target cells as previously described (23).”
Self-citationWilson, B. E., Routy, B., Nagrial, A., & Chin, V. T. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02453-2 · Cited by 152
Self-citationKhademian, M., & Imlay, J. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701587114 · Cited by 126 · cited 1×
“Thus, bacteria that associate with castalagin may be protected from ROS present at the oxic–anoxic interface of the intestinal epithelium (31, 32).”
BackgroundBourgeois‐Daigneault, M., St-Germain, L. E., Roy, D. G., Pelin, A., Aitken, A. S., Arulanandam, R., Falls, T. J., Garcia, V., Diallo, J., & Bell, J. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0744-y · Cited by 88 · cited 2×
“MCA-205 and E0771 cells were cultured as previously described (10, 20).”
MethodKuhn, P. E., Kalariya, H. M., Poulev, A., Ribnicky, D., Jaja-Chimedza, A., Roopchand, D. E., & Raskin, I. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198716 · Cited by 51
Daillère, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinská, E., De Vries, I. J. M., Naccarati, A. G., Zitvogel, V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774298 · Cited by 38 · cited 1×
“Recently, the first proof-ofprinciple FMT clinical trials in melanoma were reported, and several others evaluating FMT, probiotics, or targeted dietary modifications in combination with ICI are ongoing (17, 18).”
BackgroundSelf-citationTherapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020
Elkrief, A., Joubert, P., Florescu, M., Tehfe, M. A., Blais, N., & Routy, B. (2020) · Current Oncology · doi:10.3747/co.27.5953 · Cited by 24
Self-citationvan Heumen, B. W. H., Roelofs, H. M. J., Morsche, R. H. M. T., Marian, B., Nagengast, F. M., & Peters, W. H. M. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.004 · Cited by 22 · cited 1×
“Moreover, secondary taurinated bile acids are known to inhibit colon adenoma (27) and are decreased after ATB treatment, which has also been associated with ICI resistance (28).”
BackgroundHelicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Smith, J., Vaillant, L., Oster, P., Riva, E., McMillan, B., Begka, C., & Truntzer, C. (2022) · Figshare · doi:10.5281/zenodo.7396077 · Cited by 16
Self-citationIsnard, S., Fombuena, B., Ouyang, J., Royston, L., Lin, J. C.-Y., Bu, S., Sheehan, N. L., Lakatos, P. L., Bessissow, T., Chomont, N., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-053081 · Cited by 9 · cited 1×
“Finally, in a proof-of-principle experiment, we analyzed the feces of two non–cancer patients enrolled in a clinical trial (NCT04058392) addressing the safety of oral administration of CC (26).”
MethodSelf-citation
Cited by
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526
Self-citationTargeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
An integrated tumor, immune and microbiome atlas of colon cancer
Roelands, J., Kuppen, P. J. K., Ahmed, E. I., Mall, R., Masoodi, T., Singh, P., Monaco, G., Raynaud, C., de Miranda, N. F. C. C., Ferraro, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02324-5 · Cited by 213
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citation
Metadata
- Authors
- Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., Isnard, S., Fradet, Y., Dridi, L., Velin, D., Oster, P., Raoult, D., Ghiringhelli, F., Boidot, R., Chevrier, S., Kysela, D. T., Brun, Y. V., Falcone, E. L., Pilon, G., Oñate, F. P., Gitton-Quent, O., Le Chatelier, E., Durand, S., Kroemer, G., Elkrief, A., Marette, A., Castagner, B., & Routy, B.
- Affiliations
- Université de Montréal (CA)
- McGill University (CA)
- 1University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
- 3Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Centre Hospitalier Universitaire Vaudois (CH)
- Aix-Marseille Université (FR)
- Centre Georges François Leclerc (FR)
- Centre National de la Recherche Scientifique (FR)
- Montreal Clinical Research Institute (CA)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Université Paris-Saclay (FR)
- 14Université Paris-Saclay, INRAE, MGP, Jouy-en-Josas, France.
- 15Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
- Inserm (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Routy, Bertrand
- ORCID
- Messaoudene, Meriem
- Pidgeon, Reilly
- Richard, Corentin
- Ponce, Mayra
- Diop, Khoudia
- Nolin-Lapalme, Alexis
- Malo, Julie
- Fradet, Yves
- Dridi, Lharbi
- Velin, Dominique
- Oster, Paul
- Raoult, Didier
- Ghiringhelli, François
- Boidot, Romain
- Chevrier, Sandy
- Kysela, David T.
- Brun, Yves V.
- Falcone, Emilia Liana
- Pilon, Geneviève
- Oñate, Florian Plaza
- Gitton-Quent, Oscar
- Le Chatelier, Emmanuelle
- Kroemer, Guido
- Elkrief, Arielle
- Marette, André
- Castagner, Bastien
- Routy, Bertrand
- Venue
- Cancer Discovery
- Published
- 2022-01-14
- Volume
- 12
- Issue
- 4
- Pages
- 1070-1087
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9394387
- OpenAlex
- W4206012887
- Cited by
- 250
- References
- 36
- Citations by year
- 2026: 49 · 2025: 67 · 2024: 55 · 2023: 52 · 2022: 27
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-nd)
- Funders
- Vaccines and Immunotherapies Core of the CIHR Canadian HIV Trials Network (CTN 247)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Nursing › Nutrition and Dietetics › Pomegranate: compositions and health benefits
- Keywords
- castalagin, ellagitannins, Myrciaria dubia, gut microbiota, anti-PD-1 resistance, cancer immunotherapy, prebiotics, Ruminococcus bromii, taurine-conjugated bile acids, tumor microenvironment, fecal microbiota transplantation, anticancer activity, berry polyphenols
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Animals, Bacteria, Humans, Mice, Polyphenols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.